Dr. Phillip Febbo is Chief Scientific Officer and Chief Medical Officer at Veracyte, Inc., where he leads their global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient care needs in cancer.  Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care during a balanced career with 15 years in academic as a medical oncologist and physician scientist at Dana Farber Cancer Institute, Duke, and UCSF and a decade in Industry at Genomic Health, Illumina, and now Veracyte, Inc. Dr. Febbo has also served on as an independent director on the Boards of Varian, Inc before it’s acquisition by Siemens Healthineers and was a member of the Foundation Board of the American College of Medical Genetics and Genomics between 2018 and 2023. 

Prior to transitioning to Industry, Dr. Febbo was Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. In 2013, he joined Genomic Health as Chief Medical Officer and, after 5 years, moved to Illumina as Chief Medical Officer. 

Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke University Medical Center’s Institute of Genome Sciences and Policy. He completed his internal medicine residency at the Brigham and Women’s Hospital, and his fellowship in oncology at the Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo has served as a primary investigator for the Translational Research Program of The Alliance, an NCI-supported cooperative group, where his work focused on incorporating biomarkers into large clinical trials. He holds a bachelor's degree in Biology from Dartmouth College and a medical degree from UCSF.  

Dr. Febbo joined the Reagan-Udall Foundation for the FDA Board of Directors in 2021.